Thrombosis and Thrombolysis: Platelet Membrane Glycoproteins

Heart Lung and Circulation

Volumn 16, Issue 3, 2007, Pages 176-179

  Skinner, Michael P ^a  

^a Ramsay Health Care Westmead Private Hospital   (Australia)

Author keywords

Platelet membrane glycoproteins; Thrombolysis; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; MEMBRANE PROTEIN; PADGEM PROTEIN; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY THROMBOSIS; HEART INFARCTION; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOGENESIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASCULAR PATENCY;

BIOLOGICAL MARKERS; BLOOD PLATELETS; CORONARY ARTERIOSCLEROSIS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET MEMBRANE GLYCOPROTEINS; THROMBOSIS;

EID: 34249038461     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.03.004     Document Type: Article

References (53)

1. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. JAMA 59 (1912) 2015-2020
2. DeWood M.D., Spores J., Notske R., Lowell T.M., Burroughs R., Golden M.S., and Lang H.T. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. New Engl J Med 303 (1980) 897-902
3. Davies M.J., and Thomas A. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 53 (1985) 363-373
4. Libby P. Lesion versus lumen. Nat Med 1 (1995) 17-18
5. Skinner M.P., Yuan C., Mitsumori L., Hayes C.E., Raines E.W., Nelson J.A., and Ross R. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med 1 (1995) 69-73
6. Maseri A., and Fuster V. Is there a vulnerable plaque?. Circulation 107 (2003) 2068-2071
7. Brown B.G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high apolipoprotein B. New Engl J Med 323 (1990) 1289-1298
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
9. Bleakley Chandler A. An overview of thrombosis and platelet involvement in the development of the human atherosclerotic plaque. In: Glagov S. (Ed). Pathobiology of the Human Atherosclerotic Plaque (1990), Berlin, Springer-Verlag
10. Rokitansky C. A manual of pathological anatomy 1855;4:198-207.
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
12. Lewis H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty J.E., Schnaper H.W., Le Winter M.M., Linares E., Pouget J.M., Sabharwal S.C., Chesler E., and DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. New Engl J Med 309 (1983) 396-403
13. Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A., Jablonsky G., Kostuk W.J., Melendez L.J., and Myers M.G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. New Engl J Med 313 (1985) 1369-1375
14. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
15. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H., and Investigators F.T. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
16. Goldman S., Copeland J., Moritz T., Henderson W., Zadina K., Ovitt T., Doherty J., Read R., Chesler E., and Sako Y. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 80 (1989) 1190-1197
17. Laffel G.L., and Braunwald E. Thrombolytic therapy. A new strategy for treatment of acute myocardial infarction. New Engl J Med 311 (1984) 710-717
18. Gruppo Italiano Per Lo Studio Della Streptochinasi Nell'infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 (1986) 397-401
19. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
20. Baigent C., Collins R., Appleby P., Parish S., Sleight P., and Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both or neither. Br Med J 316 (1998) 1337-1343
21. Chesterman C.N., and Berndt M.C. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol 15 (1986) 323-353
22. Phillips D.R., Charo I.F., Parise L.V., and Fitzgerald L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71 (1988) 831-843
23. Phillips D.R., and Agin P.P. Platelet plasma membrane glycoproteins. J Biol Chem 252 (1977) 2121-2126
24. Berndt M.C., and Caen J.P. Platelet glycoproteins. Prog Hemost Thromb 7 (1984) 111-150
25. Pischel K.D., Bluestein H.G., and Woods V.L. Platelet glycoproteins Ia, Ic and IIa are physicochemically indistinguishable from the very late activation antigens adhesion related proteins of lymphocytes and other cell types. J Clin Invest 81 (1988) 505-513
26. Edelman G.M. Cell adhesion molecules. Science 219 (1983) 450-457
27. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251 (1991) 1451-1455
28. Albelda S.M., and Buck C.A. Integrins and other cell adhesion molecules. FASEB J 4 (1990) 2868-2880
29. Plantefaber F.C., and Hynes R.O. Changes in integrin receptors on oncogenically transformed cells. Cell 56 (1989) 281-290
30. Kramer R.H., and Marks N. Identification of integrin collagen receptors on human melanoma cells. J Biol Chem 264 (1989) 4684-4688
31. Hynes R.O. Integrins: a family of cell surface receptors. Cell 48 (1987) 549-554
32. Humphries M.J. The molecular basis and specificity of integrin-ligand interactions. J Cell Sci 97 (1990) 585-592
33. Butcher E.C. Cellular and molecular mechanisms that direct leukocyte traffic. Am J Pathol 136 (1990) 3-11
34. Springer T.A. Adhesion receptors of the immune system. Nature 346 (1990) 425-434
35. Gimbrone M.A. Vascular endothelium in haemostasis and thrombosis (1986), Churchill Livingstone, Edinburgh
36. Favoloro E.J., Moraitis N., Koutts J., Exner T., and Bradstock K.F. Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thromb Haemost 61 (1989) 217-224
37. Bevilacqua M.P., Pober J.S., Mendrick D.L., Cotran R.S., and Gimbrone M.A. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84 (1987) 9238-9242
38. Newman P.J., Berndt M.C., Gorski J., White G.C., Lyman S., Paddock C., and Muller W.A. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247 (1990) 1219-1222
39. Cybulsky M.I., and Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
40. Skinner M.P., Fournier D.J., Andrews R.K., Gorman J.J., Chesterman C.N., and Berndt M.C. Characterization of human platelet GMP-140 as a heparin-binding protein. Biochem Biophys Res Commun 164 (1989) 1373-1379
41. Skinner M.P., Lucas C.M., Burns G.F., Chesterman C.N., and Berndt M.C. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 266 (1991) 5371-5374
42. McEver R.P., Beckstead J.H., Moore K.L., Marshall-Carlson L., and Bainton D.F. GMP-140, a platelet a-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 84 (1989) 92-99
43. McEver R.P. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 16 (1990) 73-83
44. Dunlop L.C., Skinner M.P., Bendall L.J., Favaloro E.J., Castaldi P.A., Gorman J.J., Gamble J.R., Vadas M.A., and Berndt M.C. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 175 (1992) 1147-1150
45. Gamble J.R., Skinner M.P., Berndt M.C., and Vadas M.A. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP140. Science 249 (1990) 414-417
46. Wong C.S., GambleJR, Skinner M.P., Lucas C.M., Berndt M.C., and Vadas M.A. Adhesion protein GMP140 inhibits superoxide anion release by human neutrophils. Proc Natl Acad Sci USA 88 (1991) 2397-2401
47. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 352 (2005) 1685-1695
48. Lefkovits J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New Engl J Med 332 (1995) 1553-1559
49. Matsuno H., Stassen J.M., Vermylen J., and Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 90 (1994) 2203-2206
50. Topol E.J., Califf R.M., and Weisman H.F. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343 (1994) 881-886
51. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., and Simoons M.L. Soluble CD40 Ligand in acute coronary syndromes. New Engl J Med 348 (2003) 1104-1111
52. Freedman J.E. CD40 ligand-assessing risk instead of damage?. New Engl J Med 348 (2003) 1163-1165
53. Chong B.H., Murray B., Berndt M.C., Dunlop L.C., Bright T., and Chesterman C.N. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83 (1994) 1535-1541